Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study

In conclusion, patients with primary platinum sensitive disease who received fewer prior lines of chemotherapy were able to receive more cycles of bevacizumab, which was associated with improved overall survival. Survival worsened when bevacizumab was initiated later in the ordinal sequence of therapies.PMID:36874058 | PMC:PMC9980410 | DOI:10.22514/ejgo.2023.002

Source: European Journal of Gynaecological Oncology - March 6, 2023 Category: OBGYN Authors: Talayeh S Ghezelayagh Emily S Wu Emma L Barber Minh D Dao Emese Zsiros Renata R Urban Heidi J Gray Barbara A Goff Chirag A Shah Nikki L Neubauer James Y Dai Janos L Tanyi John B Liao Source Type: research